Aspirin prices 'rise 1000%' amid supply shortage

UK pharmacies are facing an acute aspirin shortage with the National Pharmacy Association reporting 86% of surveyed outlets unable to supply the drug and suppliers raising prices up to 1000% (one cited jump from £0.38 to £7.82 per box). About 50.9 million aspirin items were prescribed Jan–Oct, and pharmacies warn NHS reimbursement will not cover sharply higher procurement costs; the NPA is urging regulatory changes to allow prescription substitutions amid alleged manufacturing and raw-materials/import disruptions.

Analysis

Market structure: The 1000% reported price jumps and 86% of pharmacies affected signal an acute supply shock in generic aspirin (50.9m prescriptions YTD). Immediate winners are API/brand holders and wholesalers able to source inventory; losers are community pharmacies (margin squeeze vs NHS reimbursement) and patients forced to substitute or ration. Expect pricing power concentrated at a few suppliers until manufacturing/API throughput ramps, with material effects persisting for weeks–months rather than days.

Risk assessment: Key tail risks include UK government intervention (price caps or forced substitution) within 30–90 days, large-scale API plant outages, or litigation from clinical interruptions; any of these could wipe out supplier windfalls. Hidden dependencies: heavy reliance on EU-sourced APIs post‑Brexit and low channel inventory; second-order effects include durable shifts to alternative anticoagulants and accelerated onshoring capex (2–5 years). Catalysts: supplier statements, DHSC policy announcements, and quarterly manufacturing utilization reports.

Trade implications: Favor exposure to scalable CDMOs/API producers and distributors that can arbitrage shortages (e.g., CTLT, MCK, BAYN) while avoiding direct-exposure pharmacy retailers (WBA, TSCO/LSE retail peers). Use 1–2% core positions and tactical 0.5% option spreads with 3–6 month horizons to capture volatility spikes. Size shorts conservatively given regulatory tail risk; reassess at the 30–90 day policy window.

Contrarian view: Consensus assumes structural scarcity; history (penicillin shortages) shows most generic shortages resolve in 3–6 months once API flows/production expand. The market may be overpaying for permanent disruption—government relief is probable and would re-rate suppliers down sharply. Longer-term winners are firms that invest in onshore API capacity (multi-year), not short-term price takers.

Key Decisions for Investors

• Establish a 1–2% long position in Bayer AG (BAYN.DE) to capture brand/market-share upside in OTC analgesics; alternatively buy a 3-month call spread (ATM to +10% strike) sized to 0.5% portfolio risk. Exit or cut if UK announces price caps/forced substitution within 30 days or if position falls 10%.
• Initiate a 1–2% long in Catalent (CTLT) or Lonza (LONN.SW) to play CDMO/API capacity arbitrage; prefer CTLT for US liquidity. Use a 3–12 month horizon and take profits on a 20–40% gain or if announced capacity expansions materially miss timelines.
• Put on a relative-value trade: long McKesson (MCK) 1.5% and short Walgreens Boots Alliance (WBA) 0.75% to capture distributor pricing/fulfillment advantages vs retail margin pressure. Set symmetric stop-loss at 8% and reassess on any UK DHSC policy within 30–60 days.
• Deploy tactical option exposure: buy 3-month vertical call spreads on CTLT or MCK sized to 0.5% portfolio downside to profit from a volatility spike; target 30–50% return if realized vol rises >40% vs current implied vol.
• Reduce exposure to UK-listed small pharmacy/retail names by 50% within 2 weeks (cut positions to limit downside from reimbursement lag). Only rebuild after one of: (a) supplier restock confirmed, (b) DHSC issues a procurement relief statement, or (c) 30 days of normalized dispense data.